Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdaptNK Immunotherapy for Relapsed/Refractory AML
NCT07591649Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of AdaptNK in acute myeloid leukemia (AML) (4 cohorts), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started May 2026; status: recruiting.
02
Drugs
AdaptNK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07591649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591649.